Efficacy and safety of co-administered cagrilintide and semaglutide versus semaglutide alone in adults with overweight or obesity with or without type 2 diabetes in Japan and Taiwan (REDEFINE 5): a multicentre, randomised, active-controlled, phase 3a trial

Late-phase clinical trial published in The lancet. Diabetes & endocrinology (2026) covering Cagrilintide, Semaglutide.

Late-phase clinical trial. Cited by 1 other paper.

The record

• Journal: The lancet. Diabetes & endocrinology 14(6): 450-462
• Published: 2026-04-17
• PMID: 42009015 — DOI: 10.1016/s2213-8587(25)00402-4
• MeSH terms: Humans, Diabetes Mellitus, Type 2, Obesity, Hypoglycemic Agents, Treatment Outcome, Drug Therapy, Combination, Double-Blind Method, Adult, Aged, Middle Aged, Japan, Taiwan, Female, Male, Overweight, Glucagon-Like Peptide-1 Receptor Agonists, Semaglutide
• Funding: Novo Nordisk A/S
• Author countries: Denmark, India, Japan, South Korea, Taiwan

Peptide profiles: Cagrilintide, Semaglutide.

All indexed evidence: Cagrilintide trials & papers, Semaglutide trials & papers.

Related studies: Efficacy and safety of zalfermin co-administered with semaglutide in participants with…, Cagrilintide-semaglutide (CagriSema) versus semaglutide or cagrilintide in people with…, Efficacy and safety of once-weekly cagrilintide-semaglutide (CagriSema) in adults with…, Comparative Effectiveness of CagriSegma, Semaglutide, Cagrilintide and Tirzepatide in….